Descrizione

Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. Secondo StrategyHelix, the intravenous immunoglobulin market in United States is expected to increase by US$ 2.5 miliardi durante 2022-2028, in espansione ad un CAGR di 6.4% durante il periodo di previsione.

Il rapporto fornisce dati aggiornati sulle dimensioni del mercato per il periodo 2018-2021 e previsione a 2028 covering key market aspects like sales value for intravenous immunoglobulin. The United States intravenous immunoglobulin market is segmented on the basis of application, e utente finale. Based on application, the intravenous immunoglobulin market in United States is categorized into chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, altri. The immunodeficiency diseases segment held the largest share of the United States intravenous immunoglobulin market in 2021 e si prevede che manterrà la sua quota durante il periodo di previsione. In base all'utente finale, the intravenous immunoglobulin market in United States has been segmented into homecare, ospedali & clinics.

The United States intravenous immunoglobulin market is highly competitive. Key companies profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited. Competitive landscape gives a description of the competitive nature of the intravenous immunoglobulin market in United States and a description of the leading companies. Vengono individuati i principali accordi finanziari che hanno plasmato il mercato negli ultimi anni.

Il rapporto è una risorsa inestimabile per le aziende e le organizzazioni attive in questo settore. It provides a cohesive picture of the intravenous immunoglobulin market to help drive informed decision making for industry executives, decisori politici, accademico, e analisti.

Ambito del rapporto

Applicazione: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, altri
Utente finale: homecare, ospedali & clinics
Anni considerati: la presente relazione copre il periodo 2018 A 2028
Azienda menzionata: ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols S.A., Johnson & Johnson, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited

Principali vantaggi per gli stakeholder

– Get a comprehensive picture of the United States intravenous immunoglobulin market
– Identificare le strategie regionali e le priorità strategiche sulla base dei dati locali
– Individuare i settori in crescita e le tendenze per gli investimenti

Sommario

Parte 1. introduzione
– Ambito dello studio
– Periodo di studio
– Ambito geografico
– Metodologia di ricerca
Parte 2. Intravenous immunoglobulin market overview
Parte 3. Market breakdown by application
– Chronic inflammatory demyelinating polyneuropathy (CIDP)
– Chronic lymphocytic leukemia
– Congenital HIV/AIDS
– Guillain-barre syndrome (GBS)
– Hypogammaglobulinemia
– Immune thrombocytopenic purpura (ITP)
– Immunodeficiency diseases
– Kawasaki disease
– Multifocal motor neuropathy (MMN)
– Myasthenia gravis
– Altri
Parte 4. Market breakdown by end user
– Homecare
– Ospedali & clinics
Parte 5. Aziende chiave
– ADMA Biologics Inc.
– Biotest AG
– CSL Limited
– Grifols, SA.
– Johnson & Johnson
– Kedrion Biopharma Inc. (Kedrion SpA)
– LFB S.A.
– Octapharma AG
– Takeda Pharmaceutical Company Limited
Informazioni su StrategyHelix
Disclaimer